Current status and prognostic value of PD-1/PD-l1 in treatment of colorectal cancer
10.3781/j.issn.1000-7431.2020.55.195
- Author:
Ruoxi TIAN
1
Author Information
1. Department of Human Anatomy and Histoembryology, School of Basic Medicine, Tianjin Medical University
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
B7-H1 antigen;
Colorectal neoplasms;
Immunological;
Prognosis
- From:
Tumor
2020;40(3):215-222
- CountryChina
- Language:Chinese
-
Abstract:
The death rate of colorectal cancer (CRC) is the fourth in worldwide. It is an important cause of cancer-related death and seriously affects the survival and quality of life of patients. Surgery, chemotherapy and radiotherapy are the main treatments for CRC. However, the overall survival of CRC patients has not been significantly improved. So the new treatments are urgently needed. Tumor immune escape plays a key role in tumor proliferation, recurrence and metastasis. Immune checkpoints programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) play an important role in tumor immune escape. Anti-PD-1/PD-L1 therapy has become a hotspot in cancer research. More and more studies have showed anti-PD-1/PD-L1 immunotherapy has achieved remarkable efficacy in the treatment of microsatellite instability-high (MSI-H) CRC. Therefore, this paper summarizes the clinical application of anti-PD-1/PD-L1 therapy in the treatment of CRC and the various strategies to improve its low response rate. And the predictive value of PD-L1 expression on the surface of tumor cells in the prognosis of CRC is also reviewed.
